[Research of bio-performance of chitosan and chitosan being used for bacterial vaginosis].
OBJECTIVE
Discussing the chitosan' medical efficiency to treat Gynecology bacteria infectious disease by researching the bacteriostasis, biocompatibility of chitosan and analyzing the chitosan' medical efficiency to Bacterial vaginosis by clinical examination.


METHODS
The antibiotic experiment of chitosan to Candida albicans (ATCC 10231), Escherichia Coli (ATCC 25922) and Golden staphylococcus (ATCC 6538) has been studied in this paper. The vaginal irritation experimentation of chitosan to female rabbit and the sensitization experimentation of chitosan to guinea pig also have been conducted. To study the curative effect, we also coat a layer of chitosan in 20 patients' vagina.


RESULTS
The Antibacterial rate of chitosan to Candida albicans is more than 98% and to Escherichia Coli is more than 99% and to Golden staphylococcus is more than 99%. Cytotoxicity of chitosan to vagina mucosa is grade 1 and sensitization of chitosan to vagina mucosa is none and stimulation of chitosan to vagina mucosa is very slightly. The total efficiency rate to treat Gynecology bacteria infectious disease is 90% and the cure rate is 75%.
Tianjin Center of Medical Device Evaluation, 300191. cuihuisu@sina.com
Huisu
H
Cui
Wei
W
Shi
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D002176:Candida albicans / Q000187:drug effects; D048271:Chitosan / Q000494:pharmacology / Q000627:therapeutic use*; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006648:Histocompatibility; D008826:Microbial Sensitivity Tests; D011817:Rabbits; D013210:Staphylococcus / Q000187:drug effects; D016585:Vaginosis, Bacterial / Q000188:drug therapy*
D000890:Anti-Infective Agents; D048271:Chitosan